Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy [0.03%]
一名接受基因替代治疗的脊髓性肌萎缩症I型儿童出现噬血细胞性淋巴组织细胞增生症
Francesca Galletta,Ugo Cucinotta,Lucia Marseglia et al.
Francesca Galletta et al.
What is known and objective: Onasemnogene abeparvovec (OA) is the first gene replacement therapy for the treatment of paediatric patients with bi-allelic mutations in the SMN1 gene. Efficacy and safety of OA have been ass...
Extracorporeal hemoadsorption with the CytoSorb device as a potential therapeutic option in severe intoxications: Review of the rationale and current clinical experiences [0.03%]
细胞吸附技术(CytoSorb)在重度中毒治疗中的潜力：原理及临床经验综述
Darko Mitrovic,Daan W Huntjens,Elisabeth A J de Vos et al.
Darko Mitrovic et al.
What is known and objective: Many severe intoxications occur with substances with no specific antidote, which is why methods of extracorporeal elimination represent a particularly useful and even critical component in the...
Letter to the editor concerning the case report "Successful treatment of severe quetiapine intoxication with CytoSorb hemoadsorption" [0.03%]
关于案例报告“成功应用体外血液吸附治疗喹西泮中毒”的来信
Jan T Kielstein,Julius J Schmidt,Marc Ghannoum
Jan T Kielstein
Clinical features, diagnosis and management of cephalosporin-induced acute generalized exanthematous pustulosis [0.03%]
头孢菌素引起的急性广泛性发囊性皮炎的临床表现、诊断和治疗
Haibo Lei,Hongyi Deng,Xiang Liu et al.
Haibo Lei et al.
What is known and objective: Acute generalized exanthematous pustulosis (AGEP) is a serious and rare adverse reaction of cephalosporins. We aimed to describe the clinical features of cephalosporin-induced AGEP and provide...
The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials [0.03%]
Blinatumomab的药理学：药效学、药代动力学、不良反应及临床试验评估最新进展
Pauline Mocquot,Yasmine Mossazadeh,Léopoldine Lapierre et al.
Pauline Mocquot et al.
What is known and objective: Bispecific drugs (BDs) belong to the family of immunotherapies along with checkpoint inhibitors and CAR-T cells. In the field of oncology, BDs are designed to simultaneously bind a tumour anti...
Intra-articular non-steroidal anti-inflammatory drugs may promote cartilage degeneration [0.03%]
关节内非甾体抗炎药可能促进软骨退化
Katsuhiro Toda
Katsuhiro Toda
Rosuvastatin potentiates the thyrotropin-lowering effect of metformin in men with non-autoimmune subclinical hypothyroidism and prediabetes [0.03%]
Rosuvastatin增强罗格列酮联合二甲双胍治疗对PCOS患者性激素及代谢的影响
Robert Krysiak,Karolina Kowalcze,Bogusław Okopień
Robert Krysiak
What is known and objective: Metformin treatment decreases thyrotropin levels in individuals with hypothyroidism and this effect seems to be mediated by the 5'-adenosine monophosphate-activated protein kinase pathway in t...
Polymorphisms in solute carrier genes (SLC19A1, SLCO1B1, and SLCO1B3) predicts survival and toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy [0.03%]
北印度肺癌症患者进行以铂类为基础的联合化疗，溶质载体基因（SLC19A1，SLCO1B1和SLCO1B3）多态性预测生存率及毒性反应
Parul Sharma,Navneet Singh,Siddharth Sharma
Parul Sharma
What is known and objective: Solute Carrier (SLC) transporters are known mediators of drug disposition that facilitate the influx of substrates and various chemotherapeutic agents into cells. Polymorphisms in the SLC19A1,...
Evaluation of potentially inappropriate medications in older patients admitted to the cardiac intensive care unit according to the 2019 Beers criteria, STOPP criteria version 2 and Chinese criteria [0.03%]
根据2019年Beer标准、STOPP标准第二版和中国标准评估心脏重症监护病房老年患者潜在不适宜药物的可能性
Ying Bai,Jianqi Wang,Guangyao Li et al.
Ying Bai et al.
What is known and objectives: Potential inappropriate medications (PIMs) can increase the risk of medication-induced harm. However, there are no studies regarding PIMs in older and critically ill patients with cardiovascu...
Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia [0.03%]
利福霉素相关血小板减少的定量风险评估的药代动力学和药效学模拟
Tetsushu Onita,Noriyuki Ishihara,Amika Ikebuchi et al.
Tetsushu Onita et al.
What is known and objective: Linezolid (LZD) may cause thrombocytopenia, which can result in discontinuation of treatment. In this study, the blood LZD trough concentration was estimated based on population pharmacokineti...